SUBSCRIBE: eNewsletter
In an older patient wtih T2DM, HFpEF, and other comorbidities, which class of medication is guideline-recommended?
A US diabetes diagnosis is made every 21 seconds; 40% of millennials with T2DM can't pay for treatment. And there is more PCPs will want to know.
The year 2020 comes primed with 2019's approvals and expanded indications for drugs to treat patients with diabetes.
When compared to standard diet and exercise, a new review found metformin more effective in type 2 diabetes prevention.
Treatment with liraglutide for 26 weeks had no impact on bone resorption in patients with T2D, say authors of a new study.
Dapagliflozin received FDA priority review for reducing risk of CV death in adults with heart failure with reduced ejection fraction.
Cardiovascular outcomes trials of diabetes drugs have led to label expansions and guideline endorsements. Do you recall the studies and the outcomes? Find out, here.
The SGLT2 inhibitor, on October 21, 2019 was granted a label expansion from FDA for the prevention of hospitalization for heart failure in patients with T2D.
For people with type 2 diabetes, receiving motivational messages via mobile text was associated with reduced A1c vs patients who received usual care.
Less than half of PCPs responding to a recent survey chose correct values for prediabetes screening tests and seemed unaware of other evidence-based recommendations for prediabetes.
US adults with diagnosed diabetes are no closer to treatment goals than they were in 2005, according to a new study.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
